Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries.

ABSTRACT:

Objectives

The use of the NNRTI rilpivirine in low- and middle-income countries (LMICs) is under debate. The main objective of this study was to provide further clinical insights and biochemical evidence on the usefulness of rilpivirine in LMICs.

Patients and methods

Rilpivirine resistance was assessed in 5340 therapy-naive and 13,750 first-generation NNRTI-failed patients from Europe and therapy-naive HIV-1 subtype C (HIV-1C)-infected individuals from India (n = 617) and Ethiopia (n = 127). Rilpivirine inhibition and binding affinity assays were performed using patient-derived HIV-1C reverse transcriptases (RTs).

Results

Primary rilpivirine resistance was rare, but the proportion of patients with >100,000 HIV-1 RNA copies/mL pre-ART was high in patients from India an

SUBMITTER: Neogi U 

PROVIDER: S-EPMC4710214 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature